SCHEMBL1827404

SCHEMBL1827404

N#Cc1cccc(CC(C(=O)O)C(=O)OCC2c3ccccc3-c3ccccc32)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.46
EPHX2 P34913 1/20 0.41
KMT2A Q03164 2/20 0.41
FABP5 Q01469 3/20 0.40
FABP7 O15540 2/20 0.40
PIN1 Q13526 1/20 0.40
LMNA P02545 1/20 0.39
MGLL Q99685 1/20 0.39
FFAR1 O14842 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
GPR34 Q9UPC5 1/20 0.39
DPP4 P27487 1/20 0.39
FAP Q12884 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
MAOB P27338 1/20 0.38
NLRP3 Q96P20 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827402 1.00 FOLH1 (0.46) FOLH1EPHX2KMT2AFABP5FABP7
SCHEMBL2684540 0.85 FABP5 (0.49) EPHX2KMT2AFABP5FABP7
SCHEMBL2684535 0.85 FABP5 (0.49) EPHX2KMT2AFABP5FABP7
SCHEMBL9117856 0.85 EPHX2 (0.55) EPHX2KMT2AFABP5FABP7
SCHEMBL30686154 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3
SCHEMBL119454 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3
SCHEMBL29528946 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3
SCHEMBL120479 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3
SCHEMBL29907902 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3
SCHEMBL3727547 0.84 MDM4 (0.50) EPHX2KMT2AGPR34NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230419-A1 IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2011-09-22 US disclosed
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 EP disclosed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230419-A1 IAP BINDING COMPOUNDS BIRC5, BIRC7, BIRC3 FOLH1 1444/4885EPHX2 3856/4885KMT2A 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.